Symbols

MDGL

Madrigal·NASDAQ

--(--)

MDGL Profile

Madrigal Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis

Industry

Biological Technology

Established Date

Listing Date

02/06/2007

Exchange

NASDAQ Stock Exchange

Full-time Employees

915

Fiscal Year Ends

12-31

Website

www.madrigalpharma.com

Security Type

Common stock

Office address

Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania

Business

Introduction

Madrigal Pharmaceuticals, Inc., was established in March 2000 and began operations in July 2001. The company is a biopharmaceutical company focused on providing new treatments for metabolic dysfunction-related steatohepatitis. Steatohepatitis is a serious liver disease with highly unmet medical needs that can lead to cirrhosis, liver failure, cancer, liver transplant needs and premature death. The company's drug, Rezifra, is a once-daily oral liver-directed thyroid hormone receptor beta agonist designed to target a key underlying cause of MASH.